Same assigned read-only C03 role and workspace. No recursion, external models,
network, app import, tests, DB, browser, or edits. Return report only.

Owner source corrections to your prior review:
EvidenceRequirement.predicate_ids ALREADY exists in app/domain/contracts/rules.py
lines 296 onward, with RuleComponent validation, and ClausePack rehydration keeps it.
Your premise that no attribution contract exists is incorrect. Do not recommend
component-wide professional_judgment_unverified suppression: it hides another
professional judgment predicate whose own requirement is still unresolved.

Review current changes, not your previous assumptions:
- frozen_review_publication v3 calls verify_frozen_judgment_search_result before new
  publication (existing completed idempotency receipt remains historical retrieval).
- _summary_gap_requirements retains per-requirement state; _summary_gaps remains an
  equivalent set adapter for old consumers.
- new judgment_gap_selection.missing_judgment_predicates uses ONLY explicit links,
  requires all linked judgment requirements absent and empty selections; any legacy
  unattributed judgment requirement prevents this reason substitution. No accepted facts.
- frozen_review_calculation v7 passes requirement-owned gaps + missing predicate IDs.
- component_review discards only that requirement's stale PJ/OU expectation gap;
  other expectation gaps stay, all other predicates remain independent.
- expression changes only UNKNOWN reason for a validated missing-judgment selection;
  unresolved professional predicates preserve their own unverified reason.

Inspect complete affected definitions. Identify concrete mistakes, especially mixed
requirements, missing source, future nodes, existing OBSERVED evidence, and branches.
Do not call this a full semantic adoption feature. Found-judgment qualification is
still unimplemented, and no user approval was issued. Only py_compile ran.
Assess source correctness of this bounded correction and any adjacent wording
contradictions; cite files/lines. No runtime/clinical acceptance claims.
